This company develops mecillinam and pivmecillinam, antibiotics used to treat complicated and uncomplicated urinary tract infections. Their therapies target multi-drug resistant bacterial infections, providing clinicians with effective treatment options.
Funding
Funding not disclosed
Founders
Product
Problem
Urinary tract infections (UTIs) are a widespread health concern, affecting millions annually, and are increasingly difficult to treat due to rising antibiotic resistance. Current first-line treatments face challenges with declining effectiveness and safety concerns, leaving limited options for clinicians. The overuse of existing antibiotics further exacerbates the problem, contributing to the emergence of multi-drug resistant strains.
Solution
UTILITY therapeutics is dedicated to providing effective therapies to combat UTIs through novel modes of action. The company has acquired rights to two European-approved antibiotics, pivmecillinam (oral) and mecillinam (IV), offering a new treatment approach for both uncomplicated and complicated UTIs. Pivmecillinam, recommended as a first-line treatment in many countries, exhibits a unique mechanism that supports decreased resistance. Mecillinam (IV) targets a specific protein in gram-negative bacteria, demonstrating low and stable resistance, making it a crucial tool in managing infections.
Target Audience
The primary target audience includes clinicians and patients in the United States seeking effective and safe treatment options for uncomplicated and complicated UTIs, particularly those caused by multi-drug resistant bacteria.
Features
- PIVYA™ (pivmecillinam, oral) tablets for the treatment of uncomplicated UTIs, potentially as a first-line option.
- Mecillinam (IV) for the treatment of complicated UTIs.
- Unique mode of action of pivmecillinam, addressing resistance issues facing other treatments.
- Collateral sensitivity of pivmecillinam, creating an evolutionary trade-off between resistance to it and other beta-lactam antibiotics.
- Mecillinam (IV) targets penicillin-binding protein-2 (PBP-2) in the cell wall of gram-negative bacteria.
- Demonstrated consistently low and stable resistance (~5%) of Mecillinam (IV).
- Minimal likelihood of developing cross-resistance to other beta-lactam antibiotics with Mecillinam (IV).
- PIVYA™ (pivmecillinam, oral) has Qualified Infectious Disease Product (QIDP) status, granting expedited regulatory review and additional market exclusivity.